Arg-Gly-Glu-Ser

Arg-Gly-Glu-Ser;

Arg-Gly-Glu-Ser 是一种与 RGD 有关的多肽,控制 RGDS 对纤维蛋白原与激活的血小板结合的抑制活动。

Arg-Gly-Glu-Seramp;;

Arg-Gly-Glu-Ser Chemical Structure

CAS No. : 93674-97-6

规格 是否有货
100 mg ; 询价 ;
250 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

Arg-Gly-Glu-Ser 的其他形式现货产品:

Arg-Gly-Glu-Ser TFA

生物活性

Arg-Gly-Glu-Ser is a RGD-related peptide and a control for the RGDS ihibitory activity on fibrinogen binding to activated platelets.

体内研究
(In Vivo)

Arg-Gly-Glu-Ser (5 mg/kg) in combination with LPS or saline + RGDS does not affect neutrophil and macrophage cell numbers and has no effect on protein accumulation compared with LPS- or saline-treated mice, respectively[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

447.44

Formula

C16H29N7O8

CAS 号

93674-97-6

Sequence

Arg-Gly-Glu-Ser

Sequence Shortening

RGES

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

溶解性数据
In Vitro:;

H2O : 2 mg/mL (4.47 mM; Need ultrasonic and warming)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.2349 mL 11.1747 mL 22.3494 mL
5 mM
10 mM

参考文献
  • [1]. Moon C, et al. Synthetic RGDS peptide attenuates lipopolysaccharide-induced pulmonary inflammation by inhibiting integrin signaled MAP kinase pathways. Respir Res. 2009 Mar 9;10:18.

Animal Administration
[1]

Mice[1]
Mouse pharyngeal aspiration is performed in the assay. Animals are anesthetized with a mixture of ketamine and xylazine (45 mg/kg and 8 mg/kg, i.p., respectively). Test solution (30 μL) containing LPS (1.5 mg/kg) is placed posterior in the throat and aspirated into the lungs. Control mice are administrated sterile saline (0.9% NaCl). Animals are administered with RGDS or Arg-Gly-Glu-Ser peptide (1, 2.5 or 5 mg/kg, i.p.) once one hour before LPS treatment and sacrificed 4 h post-LPS. Animals are also administered RGDS or Arg-Gly-Glu-Ser peptide (5 mg/kg, i.p.) once at different time points (1 h before or 2 h after LPS treatment) and sacrificed 24 h post-LPS. In addition, animals are administered with αvβ3-blocking mAbs, anti-αv, or anti-β3 (5 mg/kg, i.p.) once 1 h before and sacrificed 4 h post-LPS. Animals administered with these mAbs 2 h after LPS treatment are sacrificed 24 h post-LPS[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Moon C, et al. Synthetic RGDS peptide attenuates lipopolysaccharide-induced pulmonary inflammation by inhibiting integrin signaled MAP kinase pathways. Respir Res. 2009 Mar 9;10:18.